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Abstract
Background: Pharmacokinetic and pharmacodynamic (PK/PD) indices are increasingly being used
in the microbiological field to assess the efficacy of a dosing regimen. In contrast to methods using
MIC, PK/PD-based methods reflect in vivo conditions and are more predictive of efficacy.
Unfortunately, they entail the use of one PK-derived value such as AUC or Cmax and may thus
lead to biased efficiency information when the variability is large. The aim of the present work was
to evaluate the efficacy of a treatment by adjusting classical breakpoint estimation methods to the
situation of variable PK profiles.
Methods and results: We propose a logical generalisation of the usual AUC methods by
introducing the concept of "efficiency" for a PK profile, which involves the efficacy function as a
weight. We formulated these methods for both classes of concentration- and time-dependent
antibiotics. Using drug models and in silico approaches, we provide a theoretical basis for
characterizing the efficiency of a PK profile under in vivo conditions. We also used the particular
case of variable drug intake to assess the effect of the variable PK profiles generated and to analyse
the implications for breakpoint estimation.
Conclusion:  Compared to traditional methods, our weighted AUC approach gives a more
powerful PK/PD link and reveals, through examples, interesting issues about the uniqueness of
therapeutic outcome indices and antibiotic resistance problems.
Background
Antimicrobial efficiency and resistance have become a
global public health issue and a real challenge for micro-
biologists, pharmaceutical companies, physicians and
other members of the health community. Inadequate use
of antibiotics promotes the selection of bacteria with
decreased susceptibility. The search for new drugs to treat
infectious diseases, the traditional approach to overcom-
ing antibiotic resistance, is growing more challenging
because multiple-resistance is becoming more prevalent
among bacteria, and new targets for antimicrobial anti-
bacterial action remain to be discovered [1-3]. The devel-
opment of new antimicrobial antibiotics is a long, costly
process, which takes a poor second place to the develop-
ment of more lucrative drugs for an aging population.
Therefore, improving the current use of antibiotics is cen-
tral to preserving their long-term effectiveness in humans
and animals. For public health officials, susceptibility test-
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ing data are crucial for the surveillance and control of
emerging resistance. To collect these data, several suscep-
tibility testing methods including dilution, disk diffusion
and automated instrument system methods are currently
in routine laboratory use [1-3]. To interpret the suscepti-
bility test results, the breakpoint, a discriminating concen-
tration, has been used to define isolates as susceptible,
intermediate or resistant [4-6]. For obvious reasons of
drug efficacy and antibiotic resistance problems, estima-
tion of breakpoints has become a necessary step in mod-
ern microbiology laboratory practice. Breakpoints are
estimated in a variety of ways, the most widely used being
the minimal inhibitory concentration (MIC), which is the
lowest concentration that completely inhibits microbial
growth [1,3,7]. Although the MIC is considered the gold
standard for breakpoint assessment, its main drawback
lies in its in vitro basis, with no drug disposition informa-
tion being included. In fact, MIC is a threshold value
while antibacterial efficacy is a complex consequence of
dynamic concentration- and time-dependent processes.
In recent decades, these limitations have led professional
groups to make intensive efforts to review pharmacoki-
netic and clinical data and establish suitable drug break-
points under in vivo conditions. One of latest tendencies
is to integrate PK/PD indices in order to understand the
relevance of drug dose and schedule to efficacy [4,8-18].
The breakpoints obtained, generally called pharmacoki-
netic/pharmacodynamic (PK/PD) breakpoints, refer to
the antibacterial concentrations calculated from the
knowledge of a PD parameter and the dimension of that
parameter for predicting efficacy in vivo [19]. The specific
PK/PD indices correlating with bacteriological efficacy
mostly depend on the nature of drug action in bacterial
killing, which may be either concentration-dependent or
time-dependent [20]. There has been a great increase in
interest in the use of PK/PD studies to estimate drug effi-
cacy since the foundation of the International Society for
Anti-infective Pharmacology (ISAP) in 1991 [20]. Whilst
these methods are more realistic as they are adapted to in
vivo conditions, they still are empirically based, lacking a
theoretical or mechanistic basis. Most importantly, the
role of variability between individuals and from other
potential sources cannot be explained in a definite way.
This situation has clearly restricted the further develop-
ment of these approaches. Because of this experimental
limitation and the complexity of the problem, there is a
need to develop new methodologies for drug evaluation.
In this work, we provide a theoretical basis for character-
izing the "efficiency" of a PK profile under in vivo condi-
tions, which will then be supported by in silico approaches
adopted for the two classes of concentration- and time-
dependent antibiotic drugs. Using this approach, break-
points can be explained and estimated within the context
of standard PK/PD analysis.
Two patterns of antibiotic performance are often used to
regroup antibacterial agents according to their bacterial
controlling activities [21-24]. The first pattern, character-
ized by concentration-dependence, refers to drugs that have
bacterial killing capacities covering a wide range of concen-
trations and effects proportional to concentration. The sec-
ond one, known as time-dependent pattern is mainly
exhibited by drugs with a saturated killing capacity directly
linked to exposure time. This class also includes antibiotics
of which the action is predominantly bacteriostatic (inhibit
bacterial growth). Although there are many reported classes
of antimicrobial agents, such agents generally fall into one
of these two major patterns [23,25]. Published work about
these two groups of drugs shows that the research commu-
nity is allocating increasing interest to this important topic.
Of particular note is the increasing popularity of PK/PD-
based methods for predicting and measuring the therapeu-
tic outcomes of these two groups of drugs [20,26]. Table 1
summarises the evolution of research on antimicrobial
agents in terms of their activity patterns and the progress in
PK/PD-based methods.
Table 1: Report on the antibacterial agents for different activity patterns and methods*
Year
Types or Methods 1970–1980 1981–1990 1991–2000 2001–2008 Drugs or parameters
Time-dependent 15 60 104 228 Beta-lactams
Macrolides
Concentration-dependent 10 80 225 315 Aminoglycosides
Fluoroquinolone
PK/PD-based methods 0 20 141 401 AUC24/MIC
Cmax/MIC
CBP
T>MIC
*The data reported in this Table have been collected using Ovid Medline® with the following keywords: concentration-dependent; time-dependent; 
antibiotic; antimicrobial; PK/PD; breakpoint; efficacy.
Some antibacterial agents such as glycopeptides and some beta-lactams are referred to as being co-dependent.Theoretical Biology and Medical Modelling 2009, 6:10 http://www.tbiomed.com/content/6/1/10
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This paper is organized as follows: In the Methods Sec-
tion, we propose a logical extension of the known efficacy
function in order to define the efficiency of a PK profile.
In the Application and Results Section, we discuss some
useful properties of our new approach and apply it to the
particular case of variable drug intake. Finally, we give a
general discussion to position our approach and findings
within the current status of the field.
Methods
Weighted AUC: a rational parameter for assessing PK/PD 
efficiency
As mentioned in the background, recently introduced PK/
PD-based breakpoint estimation was put forward to over-
come drawbacks of threshold criteria, namely MIC, which
determines in vitro antimicrobial efficacy. However, these
PK/PD-based methods use drug exposure mainly through
the AUC value (the amount of drug absorbed), whereas
the variability in drug concentration time course is not
integrated. This variability turns out to be an important
factor in drug efficacy, as widely reported [27]. In
bioequivalence studies, for example, it is common to
combine AUC and Cmax to compare PK profiles and thus
indirectly assess the expected drug efficacy. Therefore, to
rely solely on the use of these PK parameters may not be
sufficient for drawing reliable conclusions on drug effi-
cacy. To employ these parameters efficiently and optimize
their use for specific purposes, we need to adapt them by
adding more information on drug PK/PD properties.
AUC-based drug efficacy is generally assessed through sta-
tistical methods such as scatter plots. Since PK/PD proper-
ties are not fully exploited, the relationship between drug
efficacy and PK parameters only partially reflects the phar-
macological properties. If additional PK/PD properties can
be accounted for, the capacity of the actual empirical PK/
PD-based breakpoint estimation is likely to be improved.
Ideally, when a PK/PD relationship can be determined in
vivo, the power of drug efficacy prediction can be maxi-
mized. However, exact dose-response relationships under
in vivo situations are not easily accessible. This is the main
restriction that prevents full exploration of drug efficacy
prediction. Alternatively, combining the in vitro efficacy
function (E) – the PK/PD relationship measurable in the
laboratory – with AUC provides a better relationship (being
more information-loaded) than that of drug efficacy in
terms of AUC. As we will see, this combination can be con-
sidered an extension of the definition of AUC, thus relating
to specific information on drug response.
In the case of antibiotics, dose-response or concentration-
response curves against a microbial agent, also called kill-
ing or growth inhibition curves, can more easily be estab-
lished under in vitro conditions. Several functions, such as
linear, sigmoid or logistic, can be used to describe drug
efficacy [28-31]. For example, consider drug efficacy E as
a probability function expressing inhibition of bacterial
growth in response to antibiotic concentrations. It can be
modeled as:
where Emax is the maximum effect (normalized to one in
this paper), EC50 the drug concentration that attains 50%
of Emax, and H is the Hill constant [31]. Since this efficacy
function carries rich information about the response in
terms of concentration, it should and could be translated
under in vivo conditions. In fact, the in vivo situation can
be considered as a composite of many "local" in vitro
cases. "Locally in vitro" here means that once the antibiotic
reaches a certain site in the body (a target organ for exam-
ple), it behaves in a similar way as in vitro. In the follow-
ing, we will include this efficacy function E  in our
approach to predicting the drug's therapeutic perform-
ance and apply it to the case of concentration-dependent
antibiotics.
To evaluate the performance of a PK profile, we chose to
measure it by the expression efficiency, Eff, defined as fol-
lows:
where again E is a function related to drug efficacy, T is the
therapeutic duration used as a reference period and n = 0, 1, ...
Compared to AUC, E here plays the role of a weighting
function. We use it to include the information on the PK/
PD relationship as an integral part of drug efficiency meas-
urement expressed through Eff. This information can
always be updated and integrated for this purpose. For the
particular case of E = 1 and n = 1, we obtain the usual AUC
definition, thus making our newly introduced efficiency
function a direct extension of AUC.
As an illustration, we will show how the newly introduced
efficiency function can differentiate between PK profiles
with the same AUC. In Figure 1, the two PK profiles share
the same AUC but noticeably different AUCW. In fact, this
additional information level allows drug evaluation and
assessment of therapeutic performance to be refined.
Concentration-dependent antibiotics: weighted AUC 
method for antimicrobial efficiency
As mentioned, the effects of concentration-dependent
antimicrobial agents are known to be proportional to con-
centration. Their efficacy is generally assessed through
pharmacokinetic parameters, namely AUC or Cmax. To
ECt
EC t H
ECH CtH (( ) ) max ()
()
=
+ 50
(1)
Eff C C t E C t dt T n
n
T
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characterize the efficiency of concentration-dependent
drugs, we propose to use the first order version of the effi-
ciency Eff:
We notice that Eff1 contains information related to both
AUC and concentration variation levels. In this newly pro-
posed formula, these two elements are well integrated to
reflect their contributions to the evaluation of drug per-
formance. Eff1 can thus be considered an extension of the
classical approach [14]. We refer to Eff1 as the weighted
AUC and denote it by AUCW.
Time-dependent antibiotics: an analytic expression for 
total antimicrobial efficiency
The efficacy of a time-dependent drug depends on the per-
centage of time during which the concentration exceeds a
specific value CBP, generally called the breakpoint. CBP acts
as a threshold value: the drug is considered to be fully
effective when its concentration is over this value, but
non-effective otherwise (Figure 2). For time-dependent
drugs, we formulate the efficiency as:
where E = χ is the indicative function. We recall here that
the indicative function χA of a set A is defined as: χA (t) =
1 if t belongs to A; 0 otherwise. Hence, expressed in this
way, χ will be 1 if C(t) > CBP and will be 0 otherwise. We
notice that Eff0  is simply the cumulative time during
which C(t) remains above the specific concentration value
CBP, which turns out to be exactly the same classic defini-
tion for evaluating time-dependent efficacy. However,
expressing it in this way, with explicit reference to the
zero-order general efficiency Effn  function proposed
above, helps us to understand the direct relationship of
efficiency for different drug groups.
Application and results
In the following, we will focus on concentration-depend-
ent antibiotics to illustrate how the newly introduced
weighted AUC method can be used.
Efficiency equivalence between in vivo and in vitro
In pharmacology, estimation of drug efficacy is important
for optimizing a drug regimen such that the best therapeu-
tic outcome can be achieved. Generally, this estimation
should be performed under in vivo conditions. Since drug
concentrations within the body are unavoidably variable,
and in vivo-induced randomness may also be superposed,
in vivo estimation of drug efficacy is a complex problem.
Microbiologists use in vitro-based methods for estimating
antibiotic efficacy. These well-controlled in vitro studies
can result in useful partial predictors for the in vivo
Eff Eff C C t E C t dt T
T
== ò 1() ( ) (( ) ) / (3)
Eff Eff C C t E C t dt T dt T
T
tCt C
T
BP == = òò > 0
0 () ( )(( ) ) / / {: ()    } c
(4)
The left panel depicts two PK profiles with the same AUC (23.6 mg × h/L) Figure 1
The left panel depicts two PK profiles with the same AUC (23.6 mg × h/L). The solid curve illustrates rapid absorption 
while the dashed curve corresponds to slower absorption. The right panel depicts the corresponding efficacy vs time curves, 
which still show the difference in the PK profiles of the left panel; this difference is translated into the values of the corresponding 
efficiency AUCW (17.45 vs 14.40 mg × h/L). The efficacy of the high absorption regime lasts almost throughout the therapeutic 
period (24 h) beyond the target efficacy of 0.8 mg.h/L, while the lower absorption regime barely reaches this target.
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potency of drug-microorganism interactions. Very often,
efficacy-drug concentration curves are well established in
vitro. This information makes it possible to establish a cer-
tain rule for efficacy equivalence between different real PK
profiles such that the efficacy of a drug regimen can be
objectively judged. Based on the efficiency function intro-
duced above, two PK profiles are ascertained as efficiency-
equivalent, i.e.PK1 ⇔ PK2 in efficiency, if and only if they
verify the condition:
More precisely, for concentration-dependent drugs, we
can try to find a corresponding in vitro (constant) equiva-
lent concentration Ce that is likely to produce the same
efficiency provided by a given PK profile. In this case, for
a given PK profile C(t), the corresponding equivalent in
vitro concentration Ce is the solution of the equation:
For time-dependent drugs, the situation is different. The
efficiency is the percentage of time during which the con-
centration remains above a specific value CBP. As in vitro
concentrations can only have binary efficiency, we have to
determine the threshold of time percentage for an effec-
tive drug regime. The efficiency of a PK profile can be com-
pared with this threshold to measure its efficacy.
Weighted AUC method and irregular drug intake
As an application of the AUCW method, we will consider
the case of variability in PK profile generated by irregular
drug intake. It is common sense that a deviation between
real drug intake and the ideal prescribed dosing regimen
is likely to have an impact on the pharmacokinetic profile
and eventually the drug response. Non-compliance char-
acteristics can be translated into some derived PK/PD
parameters and pharmacological indices.
In a previous study, we investigated the impact of animal
feeding behaviour on the pharmacokinetics of chlortetra-
cycline (CTC), a widely-used antibiotic usually given
through animal feed [32]. We modeled a widely reported
animal feeding behaviour and associated it with the CTC
disposition model to obtain a feeding behaviour-PK
(FBPK) model. Using this model, we revealed the PK var-
iability induced by random drug intake and assessed its
main characteristics [32].
In the present paper, we will focus on the estimation of effi-
ciency of CTC in this particular context of irregular drug intake.
We have to mention that similar reasoning and analysis can be
accomplished using other sources of variability impacting
pharmacokinetics. Since CTC is a concentration-dependent
antibiotic widely used in collective medical therapy, we will
base our analysis on the method we propose for this antibiotic
class. For the purpose of illustration, we will use the individual
FBPK we previously developed [32]. The case of an animal
Eff PK Eff PK () () 12 = (5)
CEC E f fCt
ee ( ) ( ( )). = (6)
Illustration of efficacy vs. concentration of the two groups of antimicrobial agents Figure 2
Illustration of efficacy vs. concentration of the two groups of antimicrobial agents. The time-dependent microbial 
agent in the left panel has an efficiency of all or none, i.e. there is a threshold concentration above which the drug is considered 
to be fully effective, and below which it is non-effective. The performance of the concentration-dependent antimicrobial agent 
in the right panel is known to be proportional to concentration.
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population can be developed by adding the inter-variability to
the associated PK parameters. In the following, we will answer
the following questions: Can the "efficacy performance" of PK
profile be characterized uniquely by its average concentration
value? What is the extent of in vitro equivalent concentrations
that an average concentration can reach? Since we only have
access to the drug concentration in feed, what can we say
about the potential efficacy of various drug concentrations in
feed compared to that of MIC?
An advanced PK model integrating swine feeding 
behaviour: an FBPK model
In veterinary medicine, the problem of optimal use can arise
for drugs administered through feed, a widely-used practice
for therapeutic, metaphylactic or prophylactic treatment of
bacterial infections [33]. As a consequence, animal feeding
behaviour directly influences systemic exposure to drugs.
However, variation in the feeding behaviour of animals
medicated through feed has been overlooked for more than
50 years, during which feed antibiotic therapy remained
empirical. Using widely-reported descriptions of swine feed-
ing behaviour, we have mathematically formulated and inte-
grated this behaviour model into a PK model (FBPK) in
order to analyze its influence on systemic exposure to drugs
quantitatively [32]. We include here a brief review of the
FBPK model. Complete details about the model and its anal-
ysis can be found in [32].
The feeding behaviour model consists of two typical daily
feeding activities: routine peak periods complemented by
inter-peak periods of free access to feed. The routine peak
periods correspond to intense feeding activities generally
referred to as morning and afternoon peaks. Meals con-
sumed between peak periods are referred to as inter-peak
meals. The time intervals between two successive inter-
peak meals are reported to follow a Weibull distribution.
Since the animal consumes the feed in a quasi-continuous
manner during the peak periods, and considering the low
elimination rate of CTC, we have modeled the feeding
activity during these periods as an infusion process, which
gives rise to the following concentration time-course:
where [Ts, Te] is the duration of the peak period, DOSE is
the drug concentration mixed in the feed, with units in
ppm,   is the average ingestion rate, F is the bioavailabil-
ity, Ka and Ke are the absorption and elimination rates
respectively, and V is the volume of distribution.
Inter-peak meals are modeled as individual boluses enter-
ing the gastrointestinal tract because their durations are
relative short compared to the inter-meal intervals. A two-
parameter Weibull distribution is used to account for
these irregular feeding events of free access to feed. Figure
3 illustrates a typical PK profile of an animal receiving 500
ppm of drug mixed through feed.
Estimation of MIC breakpoints in animal populations
By definition, MIC breakpoints refer to critical drug con-
centrations that characterize specific antibacterial activi-
ties. The values of these MIC breakpoints are highly
pertinent to the pharmacokinetic properties as well as to
the pharmacodynamic killing capacities of these drugs
with respect to particular bacterial strains. In the clinical
setting, MIC is considered an important reference index in
choosing effective dose regimens. However, because of
the evident large variation in concentration time course
and the unavoidable pharmacokinetic variability under
the in vivo situation, the true PK/PD relationship is gener-
ally more complex. Using a single static value of MIC for
the decision process is dubious or even misleading. There-
fore we have to take account of dynamic in vivo properties
when estimating drug efficacy.
In the following, we will use the above-developed feeding
behaviour-PK model to show how one can obtain break-
point information, and of what kind, for an in vivo situa-
tion.
To do this, we adopt a Monte Carlo approach to generate,
for an animal X, possible drug inputs prior to drug dispo-
sition. The corresponding concentration time courses are
then produced with these drug inputs. To explain our
approach, we need to introduce some new concepts and
their notations.
￿ DOSE: drug concentration mixed in feed, with units
of ppm.
￿  : average over a time duration T of one concentra-
tion time course generated by Monte Carlo; it is AUC-
based.
￿  : global mean of all average concentrations  .
￿  : 95% higher mean concentration where 95%
of   are below this concentration.
C(t)=
0t T
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Ke
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￿  : 95% lower mean concentration where 95%
of   are above this concentration.
￿ :  in vitro equivalent concentration (Eq. 2) of Ci(t),
where 0 ≤ t ≤ T; it is AUCW-based.
￿  : global mean of all in vitro equivalent concentra-
tions .
￿ 95% higher in vitro equivalent concentrations  ,
where 95% of   are below this concentration
￿  : 95% lower in vitro equivalent concentrations
, where 95% of   are above this concentration.
Using the FBPK model, we can estimate the above concen-
trations versus DOSE (Figure 4). This figure shows the
95% confidence intervals of in vitro equivalent concentra-
tions   and average concentrations in terms of DOSE.
For example, given a DOSE = 400 ppm, we obtain
[ ,  ] = [0.417 mg/L, 0.450 mg/L] and
[ ,  ] = [0.397 mg/L, 0.435 mg/L].
We can consider that a DOSE is at least 95% efficiency-
equivalent to an in vitro concentration Ceff by defining
95% of equivalent in vitro concentrations generated by
this DOSE as being above Ceff. In our case, for a given
DOSE, we have the relationship Ceff  =   (Dose)
according to this 95% efficiency-equivalence criterion.
However, with each DOSE, we can also associate a 95%
confidence interval of average concentrations represented
by [  (Dose),   (Dose)] as illustrated in the
right panel of Figure 4.
Then for each at least 95% efficiency-equivalent in vitro
concentration  , it corresponds an interval of aver-
age concentrations [ ,  ]. This clearly indi-
cates that under in vivo situations, we have an associated
uncertainty in average concentrations that may corre-
spond to the same specific PK efficiency value. In other
words, the in vivo average concentration when used as a
breakpoint to indicate the efficacy of a dosing regimen can
only be interpreted probabilistically. This result is
reported in Figure 5.
To a given target value Ce (in vitro target), there corre-
sponds a DOSE that gives an interval of equivalent con-
centrations (hence equivalent efficacy) lying above Ce.
However, a given average concentration  , which is in
fact measured theoretically (using AUC for example), may
be the result of many different DOSEs. We can write this
corresponding interval as [DOSElow, DOSEhigh] as a
C L 95%
Ci
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A typical plasma drug concentration under conditions of irregular drug intake, with DOSE = 500 ppm CTC mixed in the animal  feed Figure 3
A typical plasma drug concentration under conditions of irregular drug intake, with DOSE = 500 ppm CTC 
mixed in the animal feed.
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function of  . For DOSElow, the lowest in vitro equiva-
lent concentration that can be attained by   in the sense
of 95% probability will be given by   (DOSElow).
The same applies to DOSEhigh, where the highest in vitro
equivalent concentration that can be attained by   in the
sense of 95% probability is given by   (DOSEhigh).
Hence, for each  , there is a corresponding whole inter-
val of possible in vitro equivalent concentrations given by
these two extreme values and denoted by [
(DOSElow),   (DOSEhigh)]. This result is reported
in Figure 6. The illustrated (one-to-one) relationship
between   and DOSE highlights the possibility (need) to
dissociate between the average concentration and efficacy,
thus questioning the general practice of evaluating effi-
cacy through average concentrations.
To answer the third question, we consider a MIC = 0.5 mg/
L, which is the breakpoint normally used in practice for
the evaluation of CTC efficacy. For different values of
DOSE, we estimate the probability of the in vitro equiva-
lent concentrations with values above MIC. A plot of these
probabilities versus DOSE is given in Figure 7. We can see
that for low DOSE values, it is almost certain that the ther-
apy is non-efficient while the opposite is the case for high
DOSE where success is almost secured. However, there is
a critical zone of drug concentration in feed (DOSE)
within which a given DOSE has a certain potential of suc-
cess or failure.
Robustness of weighted AUC approach
Here, we will explain and illustrate some advantageous
properties of AUCW compared to AUC. In its integration
formula, the AUCW method incorporates the in vitro effi-
cacy function E, thus penalising lower drug concentra-
tions in an appropriate way. Hence, AUCW constitutes an
improvement over AUC since the nonlinearity principle
in drug efficiency is respected (Figure 8, right panel). Also,
AUCW proves to be robust in terms of the efficacy function
E, which represents an important feature when it comes to
application. Indeed, we have generated AUCW for three
efficacy functions, namely the linear, Emax and logistic
functions. These functions along with the corresponding
AUCW are plotted in Figure 8, left and right panels respec-
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The left panel shows the in vitro equivalent concentrations versus DOSE; the solid, dotted and dash-dot lines are , ,  respectively Figure 4
The left panel shows the in vitro equivalent concentrations versus DOSE; the solid, dotted and dash-dot lines 
are ,  ,    respectively. The right panel shows the average concentrations versus DOSE; the solid, dotted 
and dash-dot lines are  ,  ,   respectively.
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tively. For sake of comparison, the AUC is also depicted
on the right panel. This figure shows that the difference
between AUC and AUCW is more noticeable than that of
the three generated AUCWs.
Discussion
Unlike the ideal in vitro conditions, where major guide-
lines for drug efficacy are routinely established for stable
drug concentrations, it is natural that high variability
arises in vivo and thus raises concerns about the applicabil-
ity of in vitro-established principles. This in vivo variability
may have various origins and forms [34,35]. One of these
sources is structural and is directly linked to drug disposi-
tion and elimination processes (generally referred to by
ADME: Absorption, Distribution, Metabolism and Elimi-
nation), where the drug concentration time course is often
described using ordinary differential equations. These
ADME scenario components are generally mimicked, sep-
arately, under laboratory conditions but hardly synthe-
sized as a whole. The well known PK parameters such as
AUC and Cmax are specifically designed to reflect this
drug exposure variation in the PK/PD association. Beyond
this structural variability, other pharmacokinetic variabil-
ity is widely recognized and turns out to be an important
influence on drug efficacy. Neglecting variability when
assessing therapeutic efficacy may lead to wrong conclu-
sions [32,35-37]. In the current article, we have shown
how, instead of relying solely on AUC or other single
parameters, the entire (in vitro or in vivo) pharmacody-
namic function should be considered in a more integrated
way for evaluating and developing antibiotic treatment
protocols. Being concerned with this issue, we have
directly generalized the classical AUC-based methods and
rendered drug evaluation more efficient by including
richer information on the PK profile.
As a static efficacy-threshold parameter widely used for
breakpoint assessment, MIC does not include drug dispo-
sition or other potential variability information. In fact,
MIC is measured under almost deterministic conditions
since variability is likely to be smaller in vitro than in vivo.
However, antibacterial efficacy is the result of a complex
dynamic process that depends on concentration and time.
Hence, relying on such in vitro values may be risky since
real in vivo values can spread over a relatively large range.
Generally, these in vitro values are used to refer to mean in
In vivo mean concentrations versus in vitro equivalent concentrations Figure 5
In vivo mean concentrations versus in vitro equivalent concentrations.
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vivo values. However, we have seen here that using the
average concentration as a reference value can lead to
ambiguous interpretation of drug efficacy since various
PK profiles are likely to share the same average concentra-
tion while having different therapeutic performances.
Under in vivo conditions, all these parameters should be
reconsidered and adapted to reflect this varying situation.
In this context, it is thus common sense to have recourse
to a probabilistic approach, as we illustrated in the exam-
ples above.
Another interesting issue arising directly from our method
concerns bacterial antibiotic resistance. It is known that
under-exposure of bacterial strains to antibiotics is the
main cause of resistance. When traditional exposure indi-
ces such as AUC or Cmax are used to evaluate drug effi-
cacy, the prediction is linearly related to antibiotic
exposure. Since these derived indices are proportional to
dose, the real mechanism of drug killing is not incorpo-
rated as the linear property remains unchanged when
either drug exposure or dose is used. In some recent work,
a trend in this direction can be noticed [28,38-40]. Using
our efficiency evaluation approach, we observe that for
low doses the traditional AUC-based method gives an
optimistic efficacy evaluation as the drug killing proper-
ties are ignored in its expression form. However, when we
account for killing properties through the efficacy curve as
we did in our efficiency formula, we clearly see that the
drug efficacy evolves more slowly than the corresponding
dose. In our example, under a 500 ppm DOSE, the drug
efficiency estimated using our method is half that of the
AUC-based method. Hence, for lower doses, there is a
good chance of being in low efficiency situations where
the risk of antibiotic resistance is higher than can be
assessed using traditional methods. These results suggest
that further investigation in this direction is needed, espe-
cially because lower doses are usually related to irregular
drug intake, such as drug holidays or cases of antibiotic
abuse. We believe that more advanced methods should be
developed to address this problem. Our approach is one
step towards this end. We propose here a logical way of
evaluating drug efficiency on the basis of in vitro efficacy
information and the PK profile. This can be relevant to
antibiotic development, especially for the estimation of
In vitro equivalent concentrations versus in vivo average concentrations Figure 6
In vitro equivalent concentrations versus in vivo average concentrations.
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Therapeutic success probability across DOSEs Figure 7
Therapeutic success probability across DOSEs. MIC = 0.5 mg/L.
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the efficacy dose in phase II. In this work, we have used
killing curves to illustrate our methods. This does not pre-
vent extension of our approach to other antibacterial
drugs. In fact, we have already suggested a possible
approach for time-dependent drugs. However, for other
complex types of effect, there is a need for further investi-
gation of the mechanism and for embedding the results in
the efficiency form that we proposed. In fact, the complex
facets of antibacterial activities are not limited to this sim-
ple classification. For some antibiotics, such as glycopep-
tides, a combination of concentration and time of
exposure may both be relevant [7,26]. The coexistence of
bactericidal and bacteriostatic properties in these drugs
makes them co-dependent on both concentration and
time. Nonetheless, the classification into concentration-
dependent and time-dependent suggested by the ISAP for
antibiotics provides an objective basis for judging antibi-
otic performance. It is interesting to note that these two
patterns fall within the two extreme cases of antibiotic
efficacy, as illustrated by the curves of Figure 2[28].
Finally, owing to the complexity of biological systems –
the human body here, as well as the mechanisms involved
in the bacteria killing capacities of drugs – new methods
are being developed every day. Some of them use very
sophisticated theories that include every known facet of
mechanism; others seek to ignore these complexities and
use elementary mathematics with an empirical philoso-
phy. The former struggle with the applicability of their
methods, while the latter often lack logistic links to the
underlying mechanism. A trade-off should be found to
balance these tendencies. We think that our article may
inspire progress on this path.
Conclusion
In this paper, we have proposed a logical generalisation of
the classical AUC method by introducing the "efficiency"
of a PK profile, which involves the efficacy function as a
weight. We have formulated these methods for both
classes of concentration-dependent and time-dependent
antibiotics. We have illustrated the approach developed
using the particular case of variable drug intake. We have
also shown how the new approach can overcome some
limitations of the classical methods for assessing drug effi-
cacy.
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